Evidence map›Paper›PMID 34509494›Full record

ArticleMetabolism: clinical and experimental2021

ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV.

M Daskou, M Sharma, W Mu, R Heymans, E Ritou, V Rezek, P Hamid, A Kossyvakis, S Sen Roy, V Grijalva and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

M DaskouDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
M SharmaDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
W MuDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
R HeymansDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
E RitouDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
V RezekDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
P HamidDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
A KossyvakisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
S Sen RoyDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
V GrijalvaDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
A ChattopadhyayDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
J PapeshDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
D MeriwetherDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
S G KitchenDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
A M FogelmanDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
S T ReddyDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Molecular Toxicology Interdepartmental Degree Program, University of California Los Angeles, Los Angeles, CA, USA.
T KelesidisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: tkelesidis@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JAMIESON-KARAVODIN, BETH DEIRDRE · 1991 to 2018
$39.9M
Viral Immunology CoreU19AI117941 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SYMONDS, GEOFFREY · 2015 to 2019
$10.6M
The role of PON2 and PON3 proteins in AtherosclerosisR01HL071776 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REDDY, SRINIVASA T. · 2003 to 2017
$4.8M
Targeting the Enterocyte to Prevent Vascular InflammationR01HL148286 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FOGELMAN, ALAN M · 2019 to 2022
$2.3M
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIVR01AG059502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI KELESIDIS, THEODOROS · 2018 to 2022
$2.0M
The role of CD4 in macrophage differentiation and functionR01AI078806 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 2009 to 2013
$1.9M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
In vivo modelling of therapeutic strategies for prevention of HIV-related fibrosis and fatty liver disease in chronic treated HIV-1 infectionR21AI136708 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$429k
Targeting Type I Interferon Immune Activation to Control HIV Infection in vivoR21AI110306 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 2014 to 2015
$424k
Humanized mice as a model to study the role of oxidized lipids in HIV-related cardiovascular diseaseR21HL134444 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS, REDDY, SRINIVASA T. · 2016 to 2017
$424k
Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related TendinopathyR43AG059501 · NIA · ZEN-BIO, INC. · PI BUEHRER, BENJAMIN M, LUDLOW, JOHN WILLIAM · 2018 to 2018
$222k
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIVR03AG059462 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$156k
NHLBI NIH HHS R01 HL071776NHLBI NIH HHS R01 HL148286NHLBI NIH HHS R21 HL134444NIAID NIH HHS K08 AI108272NIAID NIH HHS P30 AI028697NIAID NIH HHS R01 AI078806NIAID NIH HHS R21 AI110306NIAID NIH HHS R21 AI136708NIAID NIH HHS U19 AI117941NIA NIH HHS R01 AG059502NIA NIH HHS R03 AG056189NIA NIH HHS R03 AG059462NIA NIH HHS R43 AG059501
6 · The paper itself

Abstract

objectiveWe investigated whether apolipoprotein A-I (apoA-I) mimetic peptides 4F and 6F can be a novel therapeutic strategy to reduce blood and gut bioactive lipids, proinflammatory effects of endotoxin (LPS) and aberrant activation of cyclooxygenase 2 (COX-2) as instigators of increased risk for cardiometabolic disease in chronic treated HIV.

methodsWe used two humanized murine models of chronic treated HIV infection (n = 109 mice) and gut explants from HIV infected (n = 10) persons to determine whether Tg6F and 4F attenuate in vivo and ex vivo increased blood and gut bioactive lipids (measured by mass spectrometry) and intestinal protein levels of COX-2 (measured by immunoassays) in chronic treated HIV.

resultsIn these models of HIV, when compared to HIV-1 infected mice on antiretroviral therapy (ART) alone, oral Tg6F in combination with ART attenuated increases in plasma and gut bioactive lipids (and particularly COX lipids) and intestinal COX-2. 4F and Tg6F also reduced ex vivo production of COX-2 protein and associated secretion of bioactive lipids in gut explants from HIV-1 infected persons treated with LPS.

conclusionApoA-I mimetics favorably impact the proinflammatory effects of LPS, COX-2 and production of bioactive lipids that collectively drive gut and systemic inflammation in chronic treated HIV. Given prior experimental evidence that the proinflammatory effects of LPS, COX-2 and gut dysfunction contribute to cardiometabolic syndrome in chronic HIV, apoA-I mimetic peptides may be a novel therapy to treat cardiometabolic syndrome in chronic HIV.

Indexed as

AnimalsApolipoprotein A-ICyclooxygenase 2HIV InfectionsMetabolic SyndromeMicePeptidesApolipoprotein A-Iapolipoprotein A-I mimetic peptide 4FCyclooxygenase 2PeptidesApoA-I mimetic peptidesBioactive lipidsCardiometabolic syndromeChronic treated HIVEicosanoidsInflammation

Identifiers

PMID34509494
PMCPMC8802211
OpenAlexW3199919900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.